Naples Global Advisors LLC boosted its stake in AstraZeneca plc (NYSE:AZN) by 6.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 30,133 shares of the company’s stock after acquiring an additional 1,752 shares during the quarter. Naples Global Advisors LLC’s holdings in AstraZeneca were worth $1,046,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in AZN. Russell Investments Group Ltd. grew its stake in AstraZeneca by 198.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,856,140 shares of the company’s stock valued at $62,883,000 after acquiring an additional 1,235,239 shares during the period. Sector Gamma AS acquired a new stake in AstraZeneca during the 3rd quarter worth $25,094,000. Janus Henderson Group PLC boosted its stake in AstraZeneca by 5,754.0% during the 3rd quarter. Janus Henderson Group PLC now owns 726,599 shares of the company’s stock worth $24,617,000 after purchasing an additional 714,187 shares during the last quarter. Voya Investment Management LLC boosted its stake in AstraZeneca by 38.2% during the 2nd quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock worth $81,661,000 after purchasing an additional 662,481 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in AstraZeneca by 103.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,224,939 shares of the company’s stock worth $41,501,000 after purchasing an additional 621,831 shares during the last quarter. 14.75% of the stock is currently owned by hedge funds and other institutional investors.
AstraZeneca plc (NYSE AZN) traded up $0.37 during midday trading on Friday, hitting $35.44. The stock had a trading volume of 2,526,646 shares, compared to its average volume of 3,310,917. AstraZeneca plc has a fifty-two week low of $26.51 and a fifty-two week high of $35.92. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94. The stock has a market cap of $88,630.00, a price-to-earnings ratio of 25.31, a PEG ratio of 2.59 and a beta of 0.76.
Several equities research analysts have issued reports on the stock. Citigroup raised shares of AstraZeneca to a “buy” rating in a research note on Wednesday, October 18th. Zacks Investment Research cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Sanford C. Bernstein raised shares of AstraZeneca from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $30.00 to $39.00 in a research note on Friday, September 22nd. Finally, JPMorgan Chase & Co. raised shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a research note on Friday, December 29th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have assigned a buy rating to the stock. AstraZeneca has an average rating of “Hold” and a consensus target price of $34.48.
TRADEMARK VIOLATION NOTICE: This story was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3146152/astrazeneca-plc-azn-shares-bought-by-naples-global-advisors-llc.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.